The intra- and interobserver variability of PSMA-expression scores in patients with primary prostate cancer

The intra- and interobserver variability of PSMA-expression scores in patients with primary prostate cancer

Saved in:

Bibliographic Details
Main Authors:	Maarten L. Donswijk, Rosemarijn H. Ettema, Suzanne van der Gaag, Maurits Wondergem, Zing Cheung, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager
Format:	Article
Language:	English
Published:	SpringerOpen 2024-10-01
Series:	EJNMMI Research
Online Access:	https://doi.org/10.1186/s13550-024-01152-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Intra- and interobserver agreement in the diagnosis of malocclusion in sleep-disordered breathing
by: Fernando Rodrigues Carvalho, et al.
Published: (2014-02-01)

Intra‐ and interobserver reproducibility of transvaginal ultrasound for the detection and measurement of endometriotic lesions of the bowel
by: Prubpreet Chaggar, et al.
Published: (2023-10-01)

Intra- and Interobserver Reliability of Superb Microvascular Imaging (SMI) Doppler for Assessing Placental Microvasculature
by: Rocio Garcia-Jimenez, et al.
Published: (2022-07-01)

Measuring up: Ensuring Intra- and Interobserver Reliability in Stretched Penile Length with the SPLINT Technique
by: Prabudh Goel, et al.
Published: (2024-11-01)

PSMA-Targeting Radioligand Therapy in Prostate Cancer
by: Michael Wissmeyer, et al.
Published: (2024-12-01)

Weighted Kappa for Interobserver Agreement and Missing Data
by: Matthijs J. Warrens, et al.
Published: (2025-02-01)

Mammography breast density assessment with Quantra artificial intelligence software: intra- and interobserver agreement with radiologists
by: Beatriz E. Gonzalez-Ulloa, et al.
Published: (2024-10-01)

PSMA-Directed Radioligand Therapy for Metastatic Prostate Cancer
by: Ellen Heitlinger
Published: (2023-12-01)

PSMA-Directed Theragnostics: Transforming Prostate Cancer Landscape
by: Alex Friedlaender, et al.
Published: (2023-03-01)

Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases
by: Yelin Mulati, et al.
Published: (2025-07-01)

Comparing AI and Manual Segmentation of Prostate MRI: Towards AI-Driven 3D-Model-Guided Prostatectomy
by: Thierry N. Boellaard, et al.
Published: (2025-04-01)

The Performance and Role of PSMA PET Scans in Localised Prostate Cancer
by: Jianliang Liu, et al.
Published: (2025-02-01)

Androgen receptor profiling predicts prostate cancer outcome
by: Suzan Stelloo, et al.
Published: (2015-09-01)

Interobserver agreement in BPPV diagnosis using eye movement recordings
by: Ali A. Melliti, et al.
Published: (2025-08-01)

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer
by: Anna-Lena Zang, et al.
Published: (2025-09-01)

Preclinical Evaluation of a Novel PSMA-Targeted Agent <sup>68</sup>Ga-NOTA-GC-PSMA for Prostate Cancer Imaging
by: Wenjin Li, et al.
Published: (2025-03-01)

How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View
by: Daniela E. Oprea-Lager, et al.
Published: (2025-05-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

Interobserver variability in lymph node evaluation with endoscopic ultrasonography in cholangiocarcinoma
by: David Michaël de Jong, et al.
Published: (2025-01-01)

Interobserver and intra-observer variability in bowel preparation scoring for colon capsule endoscopy: impact of AI-assisted assessment, interim analysis
by: Ian Io Lei, et al.
Published: (2025-07-01)

Comparison of mammography breast density assessment by radiologists and Quantra artificial intelligence in women with and without breast implants: intra and interobserver agreement
by: Beatriz E. Gonzalez-Ulloa, et al.
Published: (2025-04-01)

Comparative analysis of intra- and interobserver reliability and validity of five basic classifications used to determine the stage of avascular necrosis of the femoral head
by: Mustafa Vezirhüyük, et al.
Published: (2025-02-01)

Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents
by: Ute Hennrich, et al.
Published: (2025-06-01)

PSMA PET/CT for prostate cancer diagnosis: current applications and future directions
by: Zhengang Shen, et al.
Published: (2025-05-01)

PSMA PET/CT in the low- to intermediate-risk prostate cancer: when and why?
by: Luca Sofia, et al.
Published: (2024-10-01)

Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer
by: Negar Abdi, et al.
Published: (2025-03-01)

Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
by: Jeremy Cheng, et al.
Published: (2025-04-01)

Incidental Findings on 18F-Fluorocholine PET/CT for Parathyroid Imaging
by: Wouter A.M. Broos, et al.
Published: (2022-09-01)

Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
by: Natalia Fulle, et al.
Published: (2022-12-01)

PSMA PET/CT scan reveals incidental meningioma in a prostate cancer patient
by: Venetia A. Florou, et al.
Published: (2025-05-01)

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01)

Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review
by: Soroush Rais-Bahrami, et al.
Published: (2025-05-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

18 The role of PSMA expression in predicting aggressive disease phenotypes in patients with prostate cancer
by: G. Gandaglia, et al.
Published: (2025-01-01)

Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
by: Jan Heilinger, et al.
Published: (2025-01-01)

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia
by: Moritz B. Bastian, et al.
Published: (2025-07-01)

Enhanced NIR-II Nanoparticle Probe for PSMA-Targeted Molecular Imaging and Prostate Cancer Diagnosis
by: Jiang Z, et al.
Published: (2025-08-01)

“Crossbreeding” NIR‐II flavchromene for PSMA‐positive prostate cancer detection and image‐guided surgery
by: Jialiang Huang, et al.
Published: (2024-09-01)

THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER
by: Duygu Has Şimşek, et al.
Published: (2021-01-01)

Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01)